AstraZeneca PLC (NASDAQ:AZN) Shares Acquired by Barlow Wealth Partners Inc.

Barlow Wealth Partners Inc. lifted its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 2.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 240,887 shares of the company’s stock after acquiring an additional 4,799 shares during the quarter. AstraZeneca comprises about 2.4% of Barlow Wealth Partners Inc.’s investment portfolio, making the stock its 12th biggest holding. Barlow Wealth Partners Inc.’s holdings in AstraZeneca were worth $18,517,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the business. Bruce G. Allen Investments LLC grew its position in AstraZeneca by 19.1% in the second quarter. Bruce G. Allen Investments LLC now owns 860 shares of the company’s stock worth $67,000 after buying an additional 138 shares during the last quarter. Carnegie Investment Counsel lifted its stake in shares of AstraZeneca by 0.8% in the 2nd quarter. Carnegie Investment Counsel now owns 17,269 shares of the company’s stock valued at $1,347,000 after purchasing an additional 138 shares during the last quarter. CANADA LIFE ASSURANCE Co lifted its stake in shares of AstraZeneca by 40.6% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 506 shares of the company’s stock valued at $34,000 after purchasing an additional 146 shares during the last quarter. Sunpointe LLC lifted its position in AstraZeneca by 4.5% during the 2nd quarter. Sunpointe LLC now owns 3,419 shares of the company’s stock worth $267,000 after acquiring an additional 147 shares during the last quarter. Finally, Argonautica Private Wealth Management Inc. lifted its position in AstraZeneca by 4.0% during the 2nd quarter. Argonautica Private Wealth Management Inc. now owns 3,874 shares of the company’s stock worth $302,000 after acquiring an additional 149 shares during the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

Analyst Ratings Changes

A number of research firms have weighed in on AZN. Deutsche Bank Aktiengesellschaft lowered shares of AstraZeneca from a “hold” rating to a “sell” rating in a research report on Friday, September 13th. Citigroup raised shares of AstraZeneca to a “strong-buy” rating in a research note on Monday, June 24th. TD Cowen upped their price objective on shares of AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Erste Group Bank upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating in a research report on Wednesday, September 11th. Finally, Barclays upgraded shares of AstraZeneca to a “strong-buy” rating in a research report on Monday, June 24th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, AstraZeneca has an average rating of “Moderate Buy” and an average price target of $89.75.

AstraZeneca Trading Down 0.2 %

AZN traded down $0.14 during mid-day trading on Wednesday, hitting $76.73. The stock had a trading volume of 388,785 shares, compared to its average volume of 5,148,180. The stock’s fifty day simple moving average is $81.57 and its 200-day simple moving average is $77.68. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.89 and a quick ratio of 0.69. The firm has a market capitalization of $237.91 billion, a price-to-earnings ratio of 37.68, a price-to-earnings-growth ratio of 1.43 and a beta of 0.46. AstraZeneca PLC has a 1-year low of $60.47 and a 1-year high of $87.68.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings data on Thursday, July 25th. The company reported $0.99 EPS for the quarter, beating the consensus estimate of $0.98 by $0.01. AstraZeneca had a net margin of 13.11% and a return on equity of 29.34%. The business had revenue of $12.45 billion for the quarter, compared to analysts’ expectations of $12.62 billion. During the same period in the previous year, the firm posted $1.08 EPS. The firm’s revenue was up 9.1% compared to the same quarter last year. As a group, research analysts forecast that AstraZeneca PLC will post 4.08 EPS for the current fiscal year.

AstraZeneca Cuts Dividend

The firm also recently declared a Semi-Annual dividend, which was paid on Monday, September 9th. Shareholders of record on Friday, August 9th were paid a $0.49 dividend. The ex-dividend date was Friday, August 9th. This represents a yield of 1.8%. AstraZeneca’s payout ratio is currently 48.04%.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.